ClinicalTrials.Veeva

Menu
V

Verum Research, LLC | Eugene, OR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Vamikibart
JNJ-81201887
Ranibizumab
BI 771716
RO7200220
Pegcetacoplan
RO7497372
OCS-01
APL 3007
Fenofibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 31 total trials

4D-150 in Patients With Diabetic Macular Edema

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Active, not recruiting
Diabetic Macular Edema
Diabetic Retinopathy
Biological: Aflibercept IVT
Biological: 4D-150 IVT

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.Substudies...

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901
Locations recently updated

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887
Locations recently updated

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidos...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: APL-3007, pegcetacoplan (APL-2)
Other: Placebo, Syfovre

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle...

Active, not recruiting
Diabetic Macular Edema
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-as...

Active, not recruiting
Diabetic Macular Edema
Drug: RO7497372

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Active, not recruiting
Geographic Atrophy
Drug: BI 1584862
Drug: Placebo-matching BI 1584862

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabeti...

Enrolling
Macular Edema
Drug: BI 1815368
Drug: Placebo

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Active, not recruiting
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-rel...

Active, not recruiting
Diabetic Macular Edema
Macular Edema
Drug: AIV007

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Choroidal Neovascularization
Wet Age-related Macular Degeneration
Genetic: ABBV-RGX-314
Biological: Ranibizumab (LUCENTIS®)

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: Sham procedure

Trial sponsors

Boehringer Ingelheim logo
4
Jaeb Center for Health Research logo
Janssen (J&J Innovative Medicine) logo
Roche logo
AbbVie logo
Aerie Pharmaceuticals logo
A
Alcon logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems